As multiple drug companies pursue treatments for FSHD, there is an urgent need to define the clinical trial strategies which will hasten drug development, including creating disease-relevant outcome measures and optimizing inclusion criteria. This proposal will develop two new outcome measures and optimize eligibility criteria by testing 160 patients in 7 sites over a period of 18 months.

Final progress update from Dr. Wagner.

Update from Dr. Wagner regarding her study of the histopathological features of FSHD affected muscle.

A proposal to study the histopathological features of muscle in a large biobank from FSHD patients and their first degree family members.